WEREWOLF THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.81 per share for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $0.81, a 53.98% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.82, a 77.72% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.22, a 66.02% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-09-30 was $1.76, a 7.85% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|---|---|
| 2025-09-30 | $0.81 10-Q · filed 2025-11-04 | $1.16 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $0.82 S-4 · filed 2026-09-22 | $1.17 S-4 · filed 2026-09-22 | |||
| 2025-03-31 | $1.22 10-Q · filed 2026-05-07 | ||||
| 2024-09-30 | $1.76 10-Q · filed 2025-11-04 | $3.57 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $3.68 10-Q · filed 2025-08-14 | $3.60 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $3.59 10-Q · filed 2025-05-08 | ||||
| 2023-09-30 | $1.91 10-Q · filed 2024-11-07 | $1.56 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $2.24 10-Q · filed 2024-08-08 | $1.55 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.48 10-Q · filed 2024-05-03 | ||||
| 2022-09-30 | $3.35 10-Q · filed 2023-11-14 | $5.00 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $2.48 10-Q · filed 2023-08-10 | $6.25 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $7.54 10-Q · filed 2023-05-11 | ||||
| 2021-09-30 | $12.75 10-Q · filed 2022-11-10 | $9.66 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $10.80 10-Q · filed 2022-08-11 | $10800000.00 10-Q · filed 2021-08-12 | $8.15 10-Q · filed 2022-08-11 | $8150000.00 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $4.23 10-Q · filed 2022-05-10 | $4230000.00 10-Q · filed 2021-06-10 | |||
| 2020-09-30 | $1.19 10-Q · filed 2021-11-10 | $1.16 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $1140000.00 10-Q · filed 2021-08-12 | $1140000.00 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $1120000.00 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |